

**Deloitte.**

**State of AI in the  
Life Sciences &  
Health Care Industry**  
The untapped edge

March 2026





# Table of contents



## Overview

About the report

03

06

## Key findings

Worker access and pilot expansion

AI transformation impacts

AI fluency and work redesign

Sovereign AI

Agentic AI

Physical AI

AI preparedness

07

07

10

13

16

18

24

30

## Tapping into AI's full potential

Close the gap between access and activation

Unlock human advantage

Build governance before scale

Address sovereign AI requirements

Build a "living" technology & data infrastructure

Pursue strategic reinvention

32

32

33

34

35

36

37

## Acknowledgements

38

## About the Deloitte AI Institute

40

## Methodology

41





# Overview

Organizations today stand at the untapped edge of AI's potential. Ongoing developments in agentic, physical, and sovereign AI present new challenges and opportunities. Momentum is building, yet the greatest gains still lie ahead as life sciences & health care (LSHC) organizations translate early progress into scalable impact. As AI expands beyond the digital core, success will ultimately hinge on a company's ability to move from ambition to activation—turning experiments and potential into real-world business value at scale.

LSHC organizations are advancing AI in an environment defined by rising care costs, regulatory complexity, data fragmentation, and mounting pressure to improve patient outcomes. Leaders are focusing on near-term value from use cases such as clinical decision support,

medical imaging and diagnostics, revenue cycle optimization, drug discovery acceleration, and supply chain resilience for critical therapies. At the same time, they are making longer-term investments in AI-enabled precision medicine, automated clinical and administrative workflows, intelligent manufacturing and quality systems, and population health management—while navigating stringent requirements for privacy, safety, and regulatory compliance.<sup>1,2</sup>

Deloitte's latest *State of AI in the Enterprise* survey captured insights from more than 375 business and IT leaders in LSHC organizations around the world with direct involvement in their companies' AI initiatives. This report explores the survey insights in detail, sharing critical actions for leaders to consider as they continue on their journey with AI.



## Overview

### Key findings

AI is moving from the pilot and experimentation phase to enterprise scaling as worker access to AI expands.

Surveyed LSHC companies have nearly doubled worker access to AI in just one year—growing from fewer than 35% to 60% of workers now equipped with sanctioned AI tools. While only 28% of respondents said their organization has moved 40% or more of their AI experiments into production to date, 57% expect to reach that level in the next three to six months.

AI transformation reveals productivity for most, business reimagination for a few.

AI is already boosting productivity and efficiency; just a subset are using it to rewrite the business. Today, 35% of LSHC companies are starting to use AI to deeply transform their businesses, 29% are redesigning key processes around AI, and the remaining 35% are only using AI at a surface level with little or no change to underlying business processes. While each are capturing productivity and efficiency gains, just the first group are truly reimagining their businesses rather than optimizing what already exists.

Companies are focused on building AI fluency instead of redesigning work around AI.

Despite high expectations for automation, 89% of LSHC companies have not redesigned jobs or the nature of work itself around AI capabilities. In line with other industries, LSHC organizations cite insufficient worker skills as the biggest barrier to integrating AI, yet fewer than half are making significant adjustments to their talent strategies. Most are focused on educating employees, but far fewer are re-architecting roles, workflows, and career paths.

## With sovereign AI taking hold, where technology is built matters as much as what it can do.

Sovereign AI is about more than technology ownership. It's about strategic independence. Almost 3 in 4 LSHC companies (74%) say the location of AI development is a key factor when choosing new technologies, signaling that geographic sovereignty is now as important as innovation. These results align with a broader, cross-industry shift toward recognizing sovereignty as a key part of decision-making.

## AI agents are scaling faster than the guardrails.

Autonomous AI agents are racing into the enterprise, but oversight is lagging. Nearly 3 in 4 (72%) LSHC companies plan to deploy agentic AI within two years. Yet, less than 1 in 5 (19%) report having a mature model for governance of autonomous agents, raising the specter of unintended risks. Overall, the current level of at least moderate agentic AI adoption in the LSHC industry (25%) aligns with the broader pattern across industries and is near the cross-industry average (23%).

## Physical AI is already embedded in operations—and its footprint is growing fast.

Physical AI is rapidly becoming integral to operations worldwide, with 57% of LSHC companies already using it to some extent and adoption projected to hit 80% within two years—consistent with the cross-industry averages of 58% and 80%, respectively.

**72%**

Nearly 3 in 4 LSHC companies plan to deploy agentic AI within two years.

## Overview

### Leaders feel more strategically ready for AI than operationally ready in infrastructure and talent.

Despite the rapid evolution of AI beyond generative AI (GenAI) to agentic and physical AI, 34% of LSHC companies believe their strategy is highly prepared for AI adoption and 28% say the same about risk and governance. Perceptions of high preparedness have shifted down slightly for talent and data management, revealing the persistent challenge of modernizing systems and skills at the speed of innovation.

**34%** of LSHC companies believe their strategy is highly prepared for AI adoption.



### About the Annual State of AI in the Enterprise Report

This annual report was fielded to 3,235 director-level to C-suite-level respondents across six industries and 24 countries between August and September 2025. Industries included: consumer; energy, resources, and industrials; financial services; life sciences & health care; technology, media, and telecom; and government and public services.\* The survey data was augmented by additional insights from 15 interviews with global C-suite executives and AI and data science leaders at large organizations across a range of industries. For details on methodology, please see page 41. This annual report is part of an ongoing series by the Deloitte AI Institute™ to help leaders in business, technology and the public sector track the rapid pace of AI change and adoption.

[Learn more. →](#)

\*Please note that government & public services survey data is not included in this analysis, given its smaller sample size and geographic focus on US organizations.

# ◆◆◆◆◆ Key findings

## AI is moving from the pilot and experimentation phase to enterprise scaling as worker access to AI expands

According to our latest survey, workforce access to AI in the LSHC industry has nearly doubled in just one year—growing from under 35% to 60% of workers with sanctioned access to AI tools. Yet, among those workers with AI access, only 24% use it in their daily workflow more than


60% of the time. This suggests that while access is widening, enterprise AI remains underutilized, and its productivity and innovation potential are still largely untapped.

### The scale acceleration is beginning

Moving from pilot to production is arguably the most important step in capturing AI value—yet this is where many companies stall. While enterprises are experimenting with AI at an accelerating pace, many struggle to scale these experiments into solutions that deliver measurable business impact.

Today, 28% of LSHC industry respondents said their organization has moved 40% or more of their AI experiments into production to date. However, 57% expect to reach that level in the next three to six months, demonstrating the pathway to value is clear and achievable. These early scalers highlight an accelerated shift from pilots to enterprise-scale. The pace of progress for LSHC companies aligns most closely with the energy, resources, and industrials industry (figure 1).

Figure 1: Organizations deploying 40%+ of AI experiments by industry (percent)



Question: In your estimation, what percentage of your AI experiments (e.g., pilots, test cases, etc.) have been deployed to date into your organization (moved into production)?

## Key findings

### The proof-of-concept trap

Why do so many pilots fail to reach production? The answer lies in a fundamental mismatch between pilot and production requirements. A pilot typically can run with a small team in a few months using cleansed data in an isolated environment. However, production deployment typically requires infrastructure investment, integration with existing systems, security reviews, compliance checks, monitoring systems, and ongoing maintenance—each of which demand significantly more resources and coordination.

In LSHC, this gap is often magnified by the need to deploy AI in highly regulated, data-sensitive, and mission-critical environments such as clinical care delivery, research and development, manufacturing, and commercial operations. Use cases spanning clinical decision support, diagnostic imaging, patient flow optimization,

drug discovery, and quality management must integrate with complex legacy systems (electronic health records, laboratory systems, manufacturing execution systems), meet strict requirements for patient safety, data privacy, and validation, and comply with evolving regulatory standards—often across fragmented organizations and data domains.

Production deployment also surfaces challenges that pilots frequently obscure in LSHC settings. Models that perform well on curated datasets or within a single institution can struggle when scaled across diverse patient populations, care settings, data standards, or manufacturing sites. Variability in clinical practice, incomplete or biased data, interoperability gaps, and shifting regulatory expectations can erode performance at scale. Timelines that appear feasible in pilots often expand once requirements for clinical validation,



## Key findings

regulatory review, cybersecurity, and clinician adoption are introduced. In production, failures are no longer theoretical—they can directly affect patient outcomes, regulatory standing, operational efficiency, or trust among clinicians and patients.

Organizations that experiment with AI often see positive results in controlled conditions but cannot consistently predict which use cases will yield the highest return on investment. This lack of clear value realization creates a vicious cycle where companies continue funding new pilots—which are relatively low cost and lower risk—rather than facing the harder work of scaling up existing successes.

The challenge of moving beyond isolated pilots to real enterprise impact is echoed by the people leading AI efforts on the ground across industries. According to one AI leader: “If there is no coherent AI strategy in organizations, you are likely to see pilot fatigue. You’re chasing the next shiny object, pressured to do something with AI without a real plan. I’ve seen many instances where people embark on pilots, but when asked how they’ll scale up if successful, they often don’t have an answer. Without a clear roadmap, executing a hundred pilots just leads to poor results and failed value creation.”



**“If there is no coherent AI strategy in organizations, you are likely to see pilot fatigue.”**

## Key findings

### AI transformation reveals productivity for most, business reimagination for a few

AI's real-world business impact in the LSHC industry is rising fast, with 85% of organizations increasing their AI investments and 78% of leaders expressing greater confidence in the technology. While 23% of leaders report that AI is having a transformative impact on their companies, many organizations are only at the edge of large-scale AI-driven transformation.

#### Beyond productivity and efficiency

AI is already delivering widespread gains in efficiency and productivity for LSHC businesses; however, other types of benefits are taking longer to achieve. In particular, revenue growth largely remains an aspiration, with 77% of LSHC

organizations hoping to grow revenue through their AI initiatives in the future compared to just 18% that are already doing so (figure 2). While LSHC companies closely match industry averages related to revenue to date, they are slightly ahead of other industries in having realized higher levels of productivity and innovation.

These numbers suggest AI is on the verge of breaking out and delivering a wide range of benefits that go far beyond efficiency and productivity improvements. Ultimately, however, success with AI isn't just about boosting efficiency or even growing revenue. It's about achieving strategic differentiation and a lasting competitive edge in the marketplace.

**Figure 2: AI benefits achieving today vs. hope to achieve in life sciences & health care** (percent)




Question: With regards to benefits from your AI efforts: Which benefits are you achieving today? Which benefits do you hope to achieve?  
N=378

The LSHC industry's approach to AI transformation is broadly in line with other industries.

**Organizations are redefining how they work, but not all are diving to the same depth**

Among the surveyed companies in the LSHC industry, just over a third (35%) are starting to use AI to deeply transform their businesses—creating new products and services, reinventing core processes, or even fundamentally changing their business models. Another 29% are redesigning key processes around AI but keeping their business models intact. And 35% are using AI at a more surface level, with little or no change to existing processes (figure 3). While each are capturing productivity and efficiency gains, only the first group are truly reimagining their businesses rather than optimizing what already exists.

Figure 3: Current approach to transformation with AI in life sciences & health care\*




Question: Which best describes your organization's current approach to process transformation during AI implementation?  
\* Figures may not sum to 100% due to rounding.  
N=378

## Key findings

The LSHC's industry's approach to AI transformation is broadly in line with other industries. LSHC organizations' use of AI for deep transformation—creating new offerings or reinventing business models—is ahead of energy, resources and industrials and financial services but is behind technology, media, and telecommunications (figure 4).

One company we interviewed took a bold, strategic approach to AI transformation by embedding AI into its core offerings and products. "AI is much more than a technology," said the company's head of AI and automation. "We wanted to give it to everyone for everyday usage and make it pervasive everywhere, but we also wanted to disrupt the market." Rather than focusing solely on internal improvements, the organization is reimagining its business by using AI to unlock new value for both itself and its clients, and to create new digital solutions and revenue streams.

**Figure 4: Current approach to transformation with AI by industry\*** (percent)



Question: Which best describes your organization's current approach to process transformation during AI implementation?

\* Figures may not sum to 100% due to rounding.

## Key findings

### Companies are focused on building AI fluency instead of redesigning work around AI

Within a year, just over a quarter of surveyed LSHC companies (28%) expect at least 10% of their jobs to be fully automated. Over the next three years, the vast majority (82%) expect at least 10% of their jobs to be fully automated.

These changes require careful thinking about career pathways. Leaders in the qualitative interviews expressed concerns about potential disruption to professional development pipelines as a result of automation. Entry-level jobs involving data entry, reconciliation, and first-level customer support at their companies are being prioritized for automation, but these jobs are often the starting point for longer careers. Organizations will likely need to develop alternate pathways for professional advancement, ensuring that employees have expertise that includes foundational processes.



**28%** of surveyed LSHC companies expect at least 10% of their jobs to be fully automated within a year.

## Key findings

### **Most companies have yet to redesign jobs around AI**

Despite high expectations for automation, 89% of LSHC companies have not redesigned jobs around AI capabilities.

AI doesn't just augment existing processes. It often requires fundamentally rethinking operating models and how work gets done.<sup>3</sup> A clinical operations manager or care team lead who has traditionally relied on clinical judgment, standard protocols, and retrospective reporting to manage patient flow and care delivery must now work alongside AI systems that generate real-time risk stratification, care pathway recommendations, and capacity forecasts. This raises questions: *When should they override the AI? How do they explain their decisions? What happens to their clinical judgment and career trajectory?*

Entry-level and task-aligned roles could be most affected, as automation may replace common, time-consuming tasks. However, as front-line jobs become more automated, supervisor and managerial roles will likely shift toward orchestration of human-AI teams. This is prompting many LSHC organizations to explore flatter structures: 47% have considered pod-based or non-hierarchical models since fewer roles require supervision of large teams; however, only 14% have moved to such models to a great or maximum extent.

### **Talent strategies are falling short**

Worker sentiment about AI is mixed but cautiously positive. While 11% of non-technical workers in the LSHC industry are highly enthusiastic about AI and are proactively seeking to use it—and 55% are at least open to exploring it—skepticism remains: 18% prefer not to use AI but will do so if required, and 2% actively distrust and avoid it.

## Key findings

According to the leaders surveyed, insufficient worker skills are the biggest barrier to integrating AI into existing workflows. Yet, fewer than half of LSHC companies are making significant adjustments to their talent strategies, with most (53%) simply focusing on educating employees to raise AI fluency (figure 5). While most are focused on educating employees, far fewer are re-architecting roles, workflows, and career paths. The LSHC industry's survey results in this area broadly align with those of the overall survey pool.

A director of AI and innovation at a major logistics organization emphasized the importance of workforce upskilling and supporting business teams as they adapt to new AI technologies: "We are reskilling our people on the business side—investing a lot to ensure they adopt the new AI tools so they can deliver bigger, better, and smarter." The company's vision for workforce transformation isn't just limited to basic upskilling. Rather, the focus is on making sure employees can move from traditional roles into more strategic

positions—supported by AI tools. "For example, in the future we would like to see AI enable today's pricing analysts to become pricing strategists."

# 53%

**of surveyed LSHC companies are focusing on educating employees to raise AI fluency.**

**Figure 5: Talent strategy adjustments due to AI in life sciences & health care** (percent)



Question: How is your organization adjusting its talent strategies because of the adoption of AI tools/capabilities?  
N=378

## Key findings

### With sovereign AI taking hold, *where* technology is built matters as much as *what* it can do


Sovereign AI is when a country—and the companies operating within it—design, train, and deploy AI under their own laws, on infrastructure they control, using locally governed data. The goal is to reduce dependence on foreign vendors for critical AI capabilities.

#### A new boardroom issue

More than 8 in 10 LSHC companies (82%) view sovereign AI as at least moderately important to their strategic planning, and nearly half (49%) rate it as very important (figure 6). LSHC organizations are in line with other industries on “moderately important” but are above the cross-industry average on “very important” (49% versus 43%).

Similarly, 67% of LSHC companies express at least moderate concern about reliance on foreign-owned AI technologies and infrastructure, with 27% very concerned (figure 7).

**Figure 6: Importance of data residency constraints and compute considerations in strategic planning in life sciences & health care\* (percent)**




● Not at all important    ● Moderately important  
● Slightly important    ● Very important

Question: How important are data residency constraints and in country/region compute considerations to your organization's strategic planning?

\* Figures may not sum to 100% due to rounding.  
N=378

**Figure 7: Level of concern over reliance on foreign-owned AI in life sciences & health care (percent)**



● Not concerned    ● Moderately concerned  
● Slightly concerned    ● Very concerned

Question: To what extent are you concerned about your organization's reliance on foreign-owned AI technologies and compute provision?

N=378

## Key findings

### Sovereign AI in practice

The rise of sovereign AI has immediate practical implications. LSHC companies working across borders must navigate complex requirements that vary by country, forcing them to build customized solutions for different markets. Almost 3 in 4 LSHC companies (74%) now factor an AI solution's country of origin into their vendor selection decisions, and nearly as many (72%) now build their AI stacks primarily with local vendors. This signals that geographic sovereignty is now as important as innovation.

As the former vice president of observability at a major global organization noted, "I've been working with a lot of international companies lately that are adamant we use an in-country infrastructure. We're taking the approach with some of those customers to do a distilled small language model for them that meets the import/export control rules because we build it in their

country. With state-run companies in particular, there is skepticism when you're using something from outside the country."

Sovereign AI pressures vary significantly by geography and industry. Only 11% of companies in the Americas rely on foreign-sourced solutions for the majority of their AI stack, compared to 32% of Europe/Middle East/Africa (EMEA) companies. In the US, state-level deployment considerations are increasingly shaping the landscape.

Ultimately, sovereign AI isn't just about technology ownership. It's about strategic independence. By building on infrastructure within its own control (fueled by its own data, models, talent, and ecosystem), a company has the ability to innovate securely and responsibly.

74%

of surveyed LSHC companies now factor an AI solution's country of origin into their vendor selection decisions.

## Key findings

### AI agents are scaling faster than the guardrails

After years of non-AI chatbots that answered basic questions, companies are now deploying sophisticated AI agents that can set goals, reason through multi-step tasks, use tools and APIs, and coordinate work with people or other agents. This shift transforms AI from a source of information and insights into a system that could perform in a different capacity.


#### Agentic AI will surge

In last year's State of AI survey, 22% of respondents in the LSHC industry said their organizations were already exploring autonomous agent development to a large or very large extent. Those early exploration efforts are now starting to translate into real-world use and are poised to drive the sharp rise in

adoption expected in the near term. Today, 25% of LSHC companies are using agentic AI at least moderately. However, within the next two years agentic AI is expected to become nearly ubiquitous in the industry, with nearly 3 in 4 LSHC companies (72%) using it at least moderately, 25% using it extensively, and 7% fully integrating it as a core component of their operations (figure 8).

The current level of at least moderate agentic AI adoption in the LSHC industry (25%) is consistent with the broader cross-industry pattern and is close to the overall weighted average of 23%. Over the next two years, adoption rates are expected to grow significantly with shared momentum across industries—aside from technology, media, and telecom, which projects a notably higher rate.

**Figure 8: Extent of agentic AI usage in life sciences & health care\*** (percent)



Question: To what extent is your organization utilizing agentic AI in its operations?

\* Figures may not sum to 100% due to rounding.

N=573

## Key findings

### AI agents unlock a vast array of use cases

While agentic AI is expected to have the highest impact in customer support, use cases for supply chain management, R&D, knowledge management, and cybersecurity are also seen as having particularly high potential.<sup>4</sup> The enterprises we interviewed across industries are already deploying AI agents across multiple functions:



**A financial services company** is building agentic workflows to automatically capture meeting actions from video conferences, draft communications to remind participants of their next steps, and track follow-through.



**An air carrier** is using AI agents to help customers complete the most common transactions, such as rebooking a flight or rerouting bags, freeing up time for human agents to address more complex matters.



**A manufacturer** is using AI agents to support new product development initiatives, leveraging AI to find the optimal balance between competing objectives such as cost and time-to-market.

**85%**

**of LSHC companies expect to customize agents to fit the unique needs of their business.**

## Key findings

### AI agents don't eliminate the value of humans

Adoption of agentic AI may increase the need for uniquely human strengths, such as adaptivity and judgement, in the near term. "We thought we were going to automate jobs," said the former VP of observability at a major global organization. "The truth is, you're not. You're going to give existing workers force multipliers where they can be more effective. Maybe someday these things will start to become headless where they just feed off a dashboard metric and you can pull back staff to wait on an alert that wakes

somebody up or flashes red on the screen if something really bad happens. But initially it is going to be more work for those people. They're not going to be cooling their heels; they're going to be watching these agents, making sure the volume metrics are right, making sure the qualitative metrics are right, and being there to interact with them if they hit a human-in-the-loop gate and need to interact with a human for accountability purposes."

**"We thought we were going to automate jobs. The truth is, you're not. You're going to give existing workers force multipliers where they can be more effective."**



## Key findings

### Managing the risks of agentic AI

Almost one in 5 (19%) LSHC companies surveyed report currently having a mature model for governance of autonomous agents. Given the technology's rapid adoption trajectory, this could be a significant limitation. As agentic AI scales from pilots to production deployments, establishing robust governance should be essential to capturing value while managing risk. For LSHC organizations, the risks can be amplified because agents may influence clinical decision support, patient triage, care coordination, trial enrollment, manufacturing quality decisions, or payer interactions—areas where errors can affect patient safety, regulatory compliance, data privacy, clinical trust, or reimbursement outcomes.

Governing agentic AI requires new approaches beyond traditional AI oversight. Unlike conventional AI systems that provide recommendations for humans to act upon, agents take actions directly—making purchases, sending communications, or modifying systems. Organizations need to establish clear boundaries for agent autonomy, defining which decisions agents can make independently versus which require human approval. Real-time monitoring systems that track agent behavior and flag anomalies are essential, as are audit trails that capture the full chain of agent actions to help ensure accountability and enable continuous improvement.



**19%**

**of LSHC companies report currently having a mature model for governance of autonomous agents.**

## Key findings

In LSHC contexts, this may include explicit guardrails around clinical, regulatory, and patient-facing actions—such as care pathway adjustments, automated prior authorization submissions, trial protocol deviations, manufacturing release decisions, or patient communications—to prevent unintended clinical, ethical, or compliance consequences.

Companies seeing the most success are taking a measured approach—starting with lower-risk use cases, building governance capabilities, and scaling deliberately. This includes cross-functional governance structures that bring together IT, legal, compliance, and business unit leaders to set policies, monitor performance, and manage escalations. Rushing to deploy agents widely before establishing these governance foundations can expose organizations to significant risks.



**Companies seeing the most success are taking a measured approach—starting with lower-risk use cases, building governance capabilities, and scaling deliberately.**

## Key findings

### A closer look at governance

## AI governance as the catalyst for growth

As AI moves from experimentation to deployment, governance is the difference between scaling successfully and stalling out. In the AI era, governance is more than guardrails—it's the catalyst for responsible growth.


The AI risks that LSHC companies are most worried about all relate to governance. Data privacy and security tops the list at 74%, followed by legal, intellectual property, and regulatory compliance (59%), governance capabilities and oversight (43%), and model quality, consistency, and explainability (43%) (figure 9).

Insights gathered during qualitative interviews with AI leaders reveal that governance is a concern. In some organizations, leaders are learning AI models have been deployed

into production without formal oversight or monitoring processes. In particular, one AI leader discovered that there wasn't a clear inventory of all the AI tools and models currently active since development efforts occurred without systematic tracking or centralized visibility over what is running in production.

Organizations that are serious about capturing AI value should treat governance as a strategic capability, not an afterthought. Those that build strong governance frameworks now will be positioned to scale AI quickly and safely. On the other hand, those that treat governance as a checkbox exercise may find themselves unable to move AI from pilot to production, held back by the very risks they failed to address.

Figure 9: AI risks most concerning in life sciences & health care (percent)



Question: Which of the following risks related to AI tools/applications is your organization most concerned about?  
N=378


## Key findings

### Physical AI is already embedded in operations—and its footprint is growing fast

Physical AI is the class of AI systems that perceive the real world, make decisions, and drive physical actions through machines or control systems. It sits at the intersection of AI and machine learning, sensors, controls, and robotics.

Physical AI integration is already expanding, with 57% of companies in the LSHC industry reporting at least limited use of physical AI, and among these, 17% are leveraging it to a moderate or greater extent. What's more, the percentage of LSHC companies using physical AI in some capacity is expected to reach 80% within two years—with 17% using physical AI extensively and 5% fully integrating it as a core element of their operations (figure 10).

Figure 10: Extent of physical AI usage in life sciences & health care (percent)



Question: To what extent is your organization currently utilizing physical AI (e.g., robotics, automated machinery) in its operations?  
N=378


## Key findings

LSHC organizations report a level of physical AI adoption—defined as moderate or greater use—in line with the cross-industry average and are expected to maintain this standing in two years (figure 11). This pattern reflects a mix of high adoption in pharma/biotech manufacturing, labs, and supply chain automation alongside slower deployment in patient-facing clinical environments, where safety risk, validation requirements, integration with legacy clinical systems, and capital/operational constraints raise the bar for scaling robotics and other physical AI.

Even as LSHC is expected to maintain an average standing, they are projecting a meaningful step-up in physical AI adoption over the next two years. Yet, physical AI's expected adoption curve is notably slower than software-based agentic AI, which is expected to jump from 25% to 72% in the same timeframe. The difference reflects the

inherent challenges of physical deployment: higher costs and capital requirements, longer development cycles, stricter safety regulations, and the need for specialized hardware and maintenance.

**Figure 11: Moderate to greater physical AI usage across industries: Now and in 2 years** (percent)



Question: To what extent is your organization currently utilizing physical AI (e.g., robotics, automated machinery) in its operations?

## Key findings

### **Controlled environments are leading the way**

Physical AI applications span a wide range of industrial and commercial settings. For example, one company we interviewed is automating package sorting and routing while granting warehouse robots more autonomy to decide where and how to store items to maximize floorspace. Other common use cases include collaborative robots (cobots) on assembly lines, inspection drones with automated response capabilities, robotic picking arms, and autonomous forklifts. Adoption is especially advanced in manufacturing, logistics, and defense, where robotics, autonomous vehicles, and drones are already reshaping operations.

In the LSHC industry, these capabilities are increasingly concentrated in controlled environments such as pharmaceutical manufacturing facilities, laboratories, hospitals, imaging centers, and distribution hubs—where

organizations are deploying physical AI to improve quality and compliance, increase throughput and capacity utilization, reduce human error, and address persistent workforce constraints.

A key factor in early adoption is environmental control. Physical AI use cases that take place in controlled domains such as factories and warehouses tend to progress much faster than use cases in open, real-world environments, where the challenges and risks are far more complex and unpredictable. For LSHC organizations, this helps explain why physical AI is advancing most rapidly in settings such as validated pharmaceutical manufacturing, laboratory automation, distribution and materials handling, and automated pharmacies—rather than in less controlled patient-facing clinical environments, where variability in human behavior, safety considerations, and regulatory oversight significantly increase complexity and risk.




## Key findings

### Types of physical AI with the greatest expected impact

As physical AI gains broader adoption, certain types are expected to have a bigger long-term impact than others in the LSHC industry—most notably, collaborative robotics (45%) and digital twins (19%) (figure 12).

These use cases rise to the top because they directly address the LSHC industry's most persistent operational and clinical challenges: rising cost pressures, workforce shortages across clinical and manufacturing roles, strict quality and regulatory requirements, and the need to improve patient outcomes while scaling access to care. Digital twins enable LSHC organizations to simulate clinical pathways, manufacturing processes, and supply chain flows—supporting scenario testing, capacity planning, and quality optimization before changes are introduced into regulated or patient-facing environments.

Figure 12: Types of physical AI expected to have the greatest impact in life sciences & health care (percent)



Question: Which area of physical AI do you believe will have the greatest impact on your industry?  
N=378

## Key findings

Collaborative robotics help augment clinicians, lab technicians, and manufacturing operators by taking on repetitive, precision-intensive, or ergonomically challenging tasks, improving consistency, throughput, and safety without fully displacing human judgment. Intelligent monitoring systems and autonomous logistics further reinforce these capabilities by improving traceability, cold-chain integrity, and real-time visibility across clinical, research, and manufacturing operations.

To help ensure public acceptance and trust of these solutions, LSHC companies should focus on making them secure, interoperable, and resilient against disruptions and cyberthreats.<sup>5</sup> Unlike software AI that operates in digital environments, physical AI systems interact with people, equipment, and infrastructure in ways that can pose safety risks if they malfunction or are compromised. This raises the stakes for testing, certification, and ongoing monitoring.

LSHC companies must also contend with complex regulatory environments that vary by industry and geography. Physical AI systems often require approval from safety regulators, compliance with industry-specific standards, and adherence to liability frameworks that don't always account for autonomous systems. These requirements add time and cost to deployment but are essential for responsible adoption.

**LSHC companies must also contend with complex regulatory environments that vary by industry and geography.**

## Key findings

### Accounting for the full cost of physical AI

In our survey, cost was cited most often as a key barrier to physical AI deployment. When evaluating business cases for physical AI, decision makers in LSHC organizations should account for total cost of ownership and not just initial equipment costs. The full picture includes facility retrofits to accommodate new equipment, sensors and robots themselves, integration with existing systems and workflows, maintenance and spare parts, and potential downtime during implementation and troubleshooting.

These costs can significantly exceed the initial investment in AI models and software. A warehouse automation project might require hundreds of thousands of dollars in AI development but millions of dollars in physical infrastructure, robotic systems, and facility modifications. Companies that underestimate these costs risk project delays or abandonment partway through implementation.


**When evaluating business cases for physical AI, decision makers in LSHC organizations should account for total cost of ownership and not just initial equipment costs.**

## Key findings

### Leaders feel more strategically ready for AI than operationally ready in infrastructure and talent

Despite the rapid evolution of AI beyond GenAI to agentic and physical AI, 34% of LSHC companies believe their strategy is highly prepared for AI adoption and 28% say the same about risk and governance (figure 13). Strategy preparedness is up from last year (+4 percentage points) but remains notably lower than the cross-industry average (42%), while risk and governance rose significantly (+11 percentage points). These areas can advance more quickly than operational readiness areas like technical infrastructure and talent because they depend primarily on executive decision-making and policy development.

Figure 13: Level of preparedness for AI adoption in life sciences & health care (percent)



Question: For each, rate your organization's level of preparedness with respect to broadly adopting AI tools/applications.  
N=378

● Percentage point change vs last year

## Key findings

Meanwhile, perceptions of high preparedness have shifted down compared with last year for talent (15%) and data management (34%) and grew only 1 percentage point for technology infrastructure (32%), revealing the persistent challenge of modernizing systems and skills at the speed of innovation. In fact, most LSHC respondents believe that resolving the key challenges for their organization's priority AI initiatives will take more than a year—far too long in today's fast-moving environment.

As a head of AI strategy we interviewed explained: “Many organizations prepared for an AI future by building infrastructure and governance for traditional AI models. With LLMs, those efforts were upended. Suddenly, there was a new capability unlike previous AI. Now, traditional AI use cases—training models from scratch, custom interfaces—have diminished. Nearly 80–90% of new use cases are generative AI. So yes, companies are prepared, but for a different future. GenAI needs a new set of capabilities.”

**“Nearly 80–90% of new use cases are generative AI. So yes, companies are prepared, but for a different future. GenAI needs a new set of capabilities.”**

# Tapping into AI's full potential

The research is telling: AI's transformational potential is real but capturing it requires far more than just technology investments. LSHC companies should treat AI as foundational. The most successful won't be those with the most AI projects or the biggest budgets, but those who build AI into the foundation of how they operate, compete, and grow.

**Here are six key focus areas to help your business capture AI's untapped edge:**



## Close the gap between access and activation

Most organizations have deployed AI tools, but far fewer have achieved meaningful usage. The gap between availability and adoption is now the primary barrier to value. Successful companies focus on activation, not just access.

High-performing implementations start with empowered employees who experiment, share early wins, and become internal champions. Top-down directives alone rarely drive meaningful change. Grassroots adoption supported by senior sponsorship creates momentum and helps ensure solutions align with real workflows.

Activation requires early attention to practical constraints: system integration, data permissions, and operational reliability. For organizations applying AI not only to digital processes but also to physical systems—such as robotics, IoT devices, or machinery—early planning for these operational realities is especially critical. Organizations that design for deployment from the outset, rather than treating scale as an afterthought, see far higher adoption. Hands-on, role-specific training and visible executive advocacy materially shift employee behavior. Leaders that treat pilots as stepping stones to production, not isolated experiments, are likely to achieve faster and more durable impact.



## Unlock human advantage by redesigning work around AI

AI is reshaping work at every level. While most organizations currently focus on personal productivity, leaders are rebuilding processes, roles, and career paths around expanded AI capabilities.

The most successful organizations reimagine jobs to seamlessly combine human strengths and AI capabilities, ensuring both aspects are used to their fullest potential. New roles—AI operations managers, human-AI interaction specialists, quality stewards, and others—signal a deeper shift: AI is now a structural component of how work is organized. Advanced organizations streamline workflows that AI can execute end-to-end, while humans focus on judgment, exception handling, and strategic oversight. The goal isn't

to replace humans or merely assist them, but to create complementary working relationships between humans and AI, in which the combined output exceeds what either could achieve alone.

Organizational structures are beginning to flatten as AI absorbs routine execution tasks. Some companies are merging technology and people-leadership functions to ensure that systems and workforce design evolve together. The pace varies by industry, but the direction is consistent: Roles, skills, and career paths should be rebuilt, not simply adjusted. Organizations should take an AI-native approach and redesign work holistically rather than layering AI onto legacy processes.



### Build governance before you scale and make it everyone's role

Governance is no longer a compliance exercise; it's the mechanism that enables rapid, confident scaling. Enterprises where senior leadership actively shapes AI governance achieve significantly greater business value than those delegating the work to technical teams alone. True governance makes oversight everyone's role, embedding it into performance rubrics so that as AI handles more tasks, humans take on active oversight. This shared responsibility empowers employees to help identify challenges and guide safe, trusted AI use.

Effective governance integrates with existing risk and oversight structures, not parallel "shadow" functions. It focuses on identifying high-risk applications, enforcing responsible design practices, and ensuring independent validation where appropriate. Leading organizations proactively monitor evolving legal requirements and build systems that can demonstrate safety, fairness, and compliance.

Autonomous systems heighten needs for data and cybersecurity governance.<sup>6</sup> Organizations need to define where humans should remain in control, how automated decisions and data use are audited, and which records of system behavior should be retained. Cross-functional teams—technology, legal, compliance, and business—establish governance frameworks early so that scale does not outpace control. At the same time, governance should be calibrated to balance risk management with innovation, ensuring that oversight enables experimentation rather than constraining it. The objective is not to add bureaucracy but to create clear, adaptive guardrails that allow responsible progress at speed.



### Address sovereign AI requirements with focus and discipline

As national governments accelerate efforts to establish sovereign AI capabilities, enterprises will likely navigate increasingly complex expectations around data control, model transparency, compliance, and localization. Sovereign AI is no longer limited to the public sector; it is reshaping requirements for every organization handling sensitive data or operating across jurisdictions. At the same time, compute strategy becomes a core component, requiring careful evaluation of both data residency and processing locations (e.g., in cloud, on-prem, hybrid, or edge environments) to remain aligned with evolving regulations and performance needs.

Leading companies take a focused approach: assessing which data and workloads must remain within national or regional boundaries, determining where local model hosting is mandatory, and clarifying how transparency, auditability, and documentation standards differ across markets. They establish clear policies for data residency, model retraining, and cross-border flows, supported by infrastructure capable of meeting multiple regulatory regimes simultaneously.

Enterprises that ignore sovereign AI constraints will face escalating operational disruption, higher compliance risk, and restricted access to key markets. Those that proactively engage build strategic advantage: They can reduce regulatory uncertainty, enhance customer trust, and position themselves as preferred partners in industries where sovereignty concerns dominate. Sovereign AI readiness is now a core element of enterprise resilience and global competitiveness, not a specialized compliance task.

## Tapping into AI's full potential



### Build a “living” technology and data infrastructure for tomorrow’s AI

Legacy data and infrastructure architectures cannot power real-time, autonomous AI. As AI capabilities extend beyond software into devices, machinery, and edge locations, organizations need to evaluate if their technology foundations are ready to support potential physical AI deployments. Modernization should create a living AI backbone: an organization-wide, real-time system that adapts dynamically to business and regulatory change, elevating infrastructure from IT initiative to strategic capability.

Leaders are enabling modular, cloud-native platforms that securely connect, govern, and integrate all data types, fostering rapid experimentation and seamless scaling. They break down silos with domain-owned data products and embed privacy, sovereignty, and

security-by-design, while enforcing enterprise standards for quality, interoperability, and lineage. This balanced approach delivers decentralized innovation supported by centralized control.

A unified, trusted data strategy is indispensable. Poor or fragmented data compounds risk and undermines every AI initiative. Forward-thinking organizations converge operational, experiential, and external data flows and invest in evolving platforms that anticipate the needs of emerging AI.<sup>7</sup> Infrastructure determines enterprise velocity; those that modernize early will likely accelerate while others remain constrained.





### Pursue strategic reinvention, not incremental efficiency

A widening performance divide separates companies treating AI as core to strategy from those viewing it as a cost-saving tool. Leading organizations invest heavily in using AI to reshape operations and create new revenue streams, resisting the pressure to chase every trending technology in favor of initiatives that genuinely advance strategic goals and deliver real value.

These organizations pursue growth across multiple horizons: strengthening current operations, expanding into adjacent markets, and building entirely new businesses enabled by AI. They rethink their organizations from the ground up and imagine how to build without legacy constraints, rather than digitizing old processes. This extends to reimagining business models and adapting to emerging trends like sovereign AI. This

intentional reinvention is one of the strongest predictors of achieving outsized returns.

Autonomous AI systems are accelerating this shift. In knowledge-intensive industries, they can absorb substantial routine work, enabling people to focus on higher-order activities. High performers are reorganizing around systems that perceive context, make decisions, and act independently, balancing bold transformation with operational continuity. They move at a pace suited to their organization's readiness, making thoughtful trade-offs and fostering informed decision-making grounded in evidence rather than hype. The strategic opportunity is discovering new sources of value that competitors cannot easily replicate.

With developments in agentic, physical, and sovereign AI rapidly expanding the boundaries of what's possible, LSHC organizations today are at the edge of tapping into AI's full potential. Whether it's figuring out how to capitalize on the latest cutting-edge innovations, making the leap from pilots to large-scale deployment, or using AI to create an enduring competitive advantage, enterprises around the world are on the edge of transforming themselves with AI. The challenge now is activation: bridging the gap from tool access to meaningful adoption, moving beyond experimentation to operationalizing AI at scale, embedding AI into core business processes—transforming technology potential into enterprise value.

# Acknowledgements

## Authors

### Business leadership

---



**Jim Rowan**  
**US Head of AI**  
Deloitte Consulting LLP  
jimrowan@deloitte.com



**Beena Ammanath**  
**Executive Director**  
**Global Deloitte AI Institute**  
Deloitte LLP  
bammanath@deloitte.com



**Nitin Mittal**  
**Principal**  
**Global AI Leader**  
Deloitte Consulting LLP  
nmittal@deloitte.com



**Costi Perricos**  
**Global GenAI**  
**Business Leader**  
Deloitte LLP  
cperricos@deloitte.co.uk

## Continue the conversation

### Industry leadership

---



**Victoria Levy**  
**Global Life Sciences**  
**& Health Care**  
**Industry Leader**  
Deloitte Consulting LLP  
vlevy@deloitte.com



**Bill Fera**  
**US Life Sciences**  
**& Health Care AI Leader**  
Deloitte Consulting LLP  
bfera@deloitte.com

## Acknowledgements

## Special thanks

### Technology and research team



**Vivek Kulkarni**  
**Managing Director**  
**US AI Transformation Leader**  
Deloitte Services LP  
vivkulkarni@deloitte.com



**Lisa Hohener**  
**Senior Manager**  
**Deloitte AI Institute**  
Deloitte Consulting LLP  
lhohener@deloitte.com



**Caroline Ritter**  
**Manager**  
**US AI Transformation**  
Deloitte Services LP  
carritter@deloitte.com

### Special thanks

#### Global AI subject matter expert network

The authors would like to thank the Deloitte subject matter specialists who contributed to the development of the survey and report:

Javier Echaniz Alonso, Bjoern Bringmann, Lou DiLorenzo, Kyle Forrest, Marcus Goetz, Cliff Goss, Scott Holcomb, Jas Jaaj, Saurabh Kumar, Anjani Kumar Sripada, Patrick Laurent, Chris Lewin, Parth Patwari, Antonio Russo, Prakul Sharma, Rohit Tandon, Ed Van Buren, Greg Vert, Blaine Woodcock.

#### Additional contributors

The authors would also like to thank our team of professionals who brought this report and campaign to life, including:

Stephanie Anderson, Andrew Ashenfelter, Hali Austin, Hannah Caslin, Vanessa Carney, Abigail Claiborne, Victoria Estacio, Behzad Eftekhari, Robert Fabbro, Alex Frole, Bharathi Gabbita, Karen Hogger, Michael Holt, Lisa Iliff, Anish Indukur, Bavapriyan K, Omar Khan, Ganapathy Subramaniam Kumar, Amy Lando, Fiona Maguire, Cullen Marriott, Meredith Mazzotta, Pamela Zamora Miranda, Hye Ra Moon, Melissa Neumann, Inal Olmez, Kendall Phillips, Jose Porras, Priyadarshini, Arockia Pulavar, Preetham Raghu, Emily Rosenberg, Kate Schmidt, Brenna Sniderman, Lesley Stephen, Tina Trabucco, Olivia Tytla, Vaibhav Vasireddy, Ivana Vucenovic, Emilie Kuo Yang.



# About the Deloitte AI Institute

The Deloitte AI Institute™ helps organizations connect all the different dimensions of the robust, highly dynamic, and rapidly evolving Artificial Intelligence ecosystem. The AI Institute leads conversations on applied AI innovation across industries, with cutting-edge insights, to promote human-machine collaboration in the “Age of With™.”

The Deloitte AI Institute aims to promote the dialogue and development of AI, stimulate innovation, and examine challenges to AI implementation and ways to address them. The AI Institute collaborates with an ecosystem composed of academic research groups, start-ups, entrepreneurs, innovators, mature AI product leaders, and AI visionaries to explore key areas of artificial intelligence including risks, policies, ethics, the future of work and talent, and applied AI use cases. Combined with Deloitte’s deep knowledge and experience in artificial intelligence applications, the Institute helps make sense of this complex ecosystem, and as a result, delivers impactful perspectives to help organizations succeed by making informed AI decisions.

No matter what stage of the AI journey you are in: whether you are a board member or a C-Suite leader driving strategy for your organization—or a hands-on data scientist bringing an AI strategy to life—the Deloitte AI Institute can help you learn more about how enterprises across the world are leveraging AI for a competitive advantage. Visit us at the Deloitte AI Institute for a full body of our work, subscribe to our podcasts and newsletter, and join us at our meet-ups and live events.

[Let's explore the future of AI together. →](#)

# Methodology

To obtain a global view of how AI is being adopted by organizations on the leading edge of AI, Deloitte surveyed 3,235 leaders between August and September 2025. Respondents were senior leaders in their organizations and included board and C-suite members, and those at the president, vice president, and director levels. The survey sample was split equally between IT and line-of-business leaders. Twenty-four countries were represented: United States (n=1,200), Canada (n=175), Brazil (n=115), Mexico (n=100), United Kingdom (n=220), Germany (n=170), France (n=150), Netherlands (n=50), Italy (n=75), Spain (n=100), Austria (n=50), Portugal (n=15), Poland (n=40), Czechia (n=30), Saudi Arabia (n=70), United Arab Emirates (n=130), Egypt (n=45), Kuwait (n=10), Qatar (n=10), Oman (n=5), Japan (n=100), India (n=200), Singapore (n=75), Australia (n=100). All participating organizations have one or more working implementations of AI being used daily. Plus, they have pilots in place to explore AI or have one or more working implementations of being used daily. Respondents were required to meet one of the following criteria with respect to their organization's AI and data science strategy, investments, implementation approach, and value measurement: influence decision-making, are part of a team that makes decisions, are the final decision-maker, or manage or oversee AI technology implementations. All statistics noted in this report and its graphics are derived from Deloitte's annual survey, conducted between August and September 2025; *The State of AI in the Enterprise* report series. N (Total leader survey responses) = 3,235. The survey data was supplemented with case studies and qualitative findings derived from 15 interviews with executives and AI and data science leaders at large organizations across a range of industries and countries.

## Endnotes

1. Pete Lyons, Todd Konersmann, Sheryl Jacobson, Nico Kleyn, Kavita Rekhraj, Darshan Gosalia, "2026 Life Sciences Outlook," December 9, 2025, <https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html>, accessed January 13, 2026.
2. Sara Siegel, Minni Sarkka-Hietala, Kavita Rekhraj, Filipe Piteira Ganhao, "2026 Global Health Care Outlook," December 11, 2025, <https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-global-health-care-outlook.html>, accessed January 13, 2026.
3. Sue Cantrell, David Mallon, Aniket Bandekar and Simona Spelman, "The path to achieving value from AI: Scaling your human edge," Deloitte Insights2Action", October 2025, <https://action.deloitte.com/insight/4740/the-path-to-achieving-value-from-ai-scaling-your-human-edge>, accessed December 12, 2025.
4. Nitin Mittal, Beena Ammanath and Jim Rowan, "The AI Dossier," The Deloitte AI Institute, <https://www.deloitte.com/content/dam/assets-zone3/us/en/docs/services/consulting/2025/ai-institute-ai-use-cases-10-06-2025.pdf>, accessed December 12, 2025.
5. Mark Osis, Raquel Buscaino, and Caroline Brown, "Robotics & Physical AI: Intelligence in motion," Deloitte, November 2025, <https://www.deloitte.com/content/dam/assets-zone3/us/en/docs/about/2025/robotics-and-physical-ai-tech-futures-report.pdf>, accessed December 12, 2025.
6. Sunny Aziz, Adnan Amjad, Naresh Persaud, Mark Nicholson, and Ed Burns, "Tech Trends 2026: The AI dilemma: Securing and leveraging AI for cyber defense," Deloitte, December 2025, <https://www.deloitte.com/us/en/insights/topics/technology-management/tech-trends/2026/using-ai-in-cybersecurity.html>, accessed December 12, 2025.
7. Vivek Kulkarni, Scott Holcomb, Prakul Sharma, Greg Vert and Caroline Ritter, "Agentic enterprise 2028: A blueprint for cost savings, job creation, and faster growth through agentic AI," Deloitte, September 2025, p. 14, <https://www.deloitte.com/us/en/what-we-do/capabilities/applied-artificial-intelligence/articles/agentic-ai-enterprise-2028.html>, accessed December 12, 2025.



## About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), its global network of member firms, and their related entities (collectively, the “Deloitte organization”). DTTL (also referred to as “Deloitte Global”) and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please see [www.deloitte.com/about](http://www.deloitte.com/about) to learn more.

Deloitte provides leading professional services to nearly 90% of the Fortune Global 500® and thousands of private companies. Our people deliver measurable and lasting results that help reinforce public trust in capital markets and enable clients to transform and thrive. Building on its 180-year history, Deloitte spans more than 150 countries and territories. Learn how Deloitte’s approximately 460,000 people worldwide make an impact that matters at [www.deloitte.com](http://www.deloitte.com).

This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited (DTTL), its global network of member firms or their related entities (collectively, the “Deloitte organization”) is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.

No representations, warranties or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of DTTL, its member firms, related entities, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. DTTL and each of its member firms, and their related entities, are legally separate and independent entities.